2366152-15-8
中文名稱
化合物 RPT193
英文名稱
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-
CAS
2366152-15-8
分子式
C27H34Cl3N5O2
分子量
566.95
MOL 文件
2366152-15-8.mol
2366152-15-8 結(jié)構(gòu)式
基本信息
中文別名
化合物 RPT193 英文別名
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-物理化學(xué)性質(zhì)
沸點(diǎn)706.9±70.0 °C(Predicted)
密度1.387±0.06 g/cm3(Predicted)
儲存條件-20°C儲存
酸度系數(shù)(pKa)4.09±0.20(Predicted)
形態(tài)Solid
顏色White to off-white
應(yīng)用領(lǐng)域
用途一
Zelnecirnon, also known as RPT193, is a CCR4 antagonist that blocks the recruitment of Th2 cells in order to treat inflammatory diseases (taken orally). The Phase 1b trial, which was conducted in patients with atopic dermatitis, found that markable improvement occurred after 4 weeks with little side effects. A Phase 2 clinical trial is currently being conducted to evaluate the efficacy and safety of Zelnecirnon, with an expected end date of September 2023.